Shockwave Medical
Revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque.
Launch date
Employees
Market cap
AUD19.4b
Enterprise valuation
AUD18.6b (Public information from Jun 2024)
Share price
$334.79 SWAV
Company register number HRB 14070 (Kleve)
Santa Clara California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 67.8m | 237m | 490m | 730m | 921m | 1.1b | 1.4b |
% growth | 58 % | 250 % | 107 % | 49 % | 26 % | 23 % | 21 % |
EBITDA | (64.4m) | (7.7m) | 123m | 192m | 263m | 350m | 427m |
% EBITDA margin | (95 %) | (3 %) | 25 % | 26 % | 29 % | 31 % | 31 % |
Profit | (65.7m) | (9.1m) | 216m | 147m | 187m | 243m | 302m |
% profit margin | (97 %) | (4 %) | 44 % | 20 % | 20 % | 21 % | 22 % |
EV / revenue | 49.7x | 25.8x | 14.6x | 9.3x | 12.9x | 11.1x | 9.2x |
EV / EBITDA | -52.3x | -789.8x | 58.3x | 35.4x | 45.2x | 35.9x | 29.4x |
R&D budget | 36.9m | 50.5m | 81.7m | 146m | - | - | - |
R&D % of revenue | 54 % | 21 % | 17 % | 20 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$12.5m | Series A | ||
$40.0m | Series B | ||
$45.0m | Series C | ||
$35.0m | Series C | ||
$15.0m | Series D | ||
N/A | $97.0m Valuation: $457m 37.3x EV/LTM Revenues -11.4x EV/LTM EBITDA | IPO | |
$89.0m Valuation: $1.5b 33.9x EV/LTM Revenues -29.4x EV/LTM EBITDA | Secondary | ||
* | N/A | $650m | Post IPO Convertible |
* | $8.8m | Post IPO Equity | |
* | $13.1b Valuation: $13.1b 17.9x EV/LTM Revenues 68.4x EV/LTM EBITDA | Acquisition | |
Total Funding | AUD228m |